Safety and efficacy of osimertinib rechallenge or continuation after pneumonitis: A multicentre retrospective cohort study.
Imaji M, Fujimoto D, Sato Y, Sakata Y, Oya Y, Tamiya M, Suzuki H, Ikeda H, Kijima T, Matsumoto H, Kanazu M, Hino A, Inaba M, Tsukita Y, Arai D, Maruyama H, Hara S, Tsumura S, Kobe H, Sumikawa H, Sakata S, Yamamoto N.
Imaji M, et al.
Eur J Cancer. 2023 Jan;179:15-24. doi: 10.1016/j.ejca.2022.10.029. Epub 2022 Nov 12.
Eur J Cancer. 2023.
PMID: 36470023